SRC and non-small cell lung carcinoma: Because cMet, FAK, and Src signaling can be bi‐directional (Sen et al, 2011), we used inhibitors of cMet (tepotinib), FAK (VS6063), Src (dasatinib), and Plk1 (volasertib) to distinguish the properties of this signaling axis in NSCLC cell lines (Fig 3E).